Found 9 hits for monomerid = 50527406 Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kcal/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Tyrosine-protein kinase JAK3
(Homo sapiens (Human)) | BDBM50527406
(CHEMBL4588333 | US10981911, Example 45)Show SMILES Fc1ccc(CNC(=O)Cc2nc3cnc4[nH]ccc4c3n2[C@H]2CC[C@H](CC#N)CC2)cc1 |r,wU:22.24,wD:25.28,(4.15,-4.61,;4.92,-5.95,;6.47,-5.94,;7.24,-7.28,;6.46,-8.6,;7.24,-9.93,;8.78,-9.93,;9.55,-11.26,;8.78,-12.6,;11.09,-11.26,;11.86,-12.6,;11.24,-14,;12.38,-15.02,;12.38,-16.56,;13.71,-17.33,;15.04,-16.56,;16.52,-17.04,;17.43,-15.79,;16.52,-14.53,;15.04,-15.01,;13.7,-14.25,;13.38,-12.75,;14.41,-11.61,;13.94,-10.15,;14.97,-9,;16.48,-9.33,;17.52,-8.18,;19.02,-8.51,;20.53,-8.84,;16.95,-10.79,;15.93,-11.93,;4.93,-8.62,;4.16,-7.29,)| Show InChI InChI=1S/C25H25FN6O/c26-18-5-1-17(2-6-18)14-29-23(33)13-22-31-21-15-30-25-20(10-12-28-25)24(21)32(22)19-7-3-16(4-8-19)9-11-27/h1-2,5-6,10,12,15-16,19H,3-4,7-9,13-14H2,(H,28,30)(H,29,33)/t16-,19- | PDB
Reactome pathway
KEGG
UniProtKB/SwissProt
UniProtKB/TrEMBL
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | 174 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of JAK3-JH1/JH2 domain (512 to 1124 residues) (unknown origin) pre-incubated before NH2-KGGEEEEYFELVKK-CO2 substrate addition and measured... |
J Med Chem 63: 2915-2929 (2020)
Article DOI: 10.1021/acs.jmedchem.9b01439 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase JAK1
(Homo sapiens (Human)) | BDBM50527406
(CHEMBL4588333 | US10981911, Example 45)Show SMILES Fc1ccc(CNC(=O)Cc2nc3cnc4[nH]ccc4c3n2[C@H]2CC[C@H](CC#N)CC2)cc1 |r,wU:22.24,wD:25.28,(4.15,-4.61,;4.92,-5.95,;6.47,-5.94,;7.24,-7.28,;6.46,-8.6,;7.24,-9.93,;8.78,-9.93,;9.55,-11.26,;8.78,-12.6,;11.09,-11.26,;11.86,-12.6,;11.24,-14,;12.38,-15.02,;12.38,-16.56,;13.71,-17.33,;15.04,-16.56,;16.52,-17.04,;17.43,-15.79,;16.52,-14.53,;15.04,-15.01,;13.7,-14.25,;13.38,-12.75,;14.41,-11.61,;13.94,-10.15,;14.97,-9,;16.48,-9.33,;17.52,-8.18,;19.02,-8.51,;20.53,-8.84,;16.95,-10.79,;15.93,-11.93,;4.93,-8.62,;4.16,-7.29,)| Show InChI InChI=1S/C25H25FN6O/c26-18-5-1-17(2-6-18)14-29-23(33)13-22-31-21-15-30-25-20(10-12-28-25)24(21)32(22)19-7-3-16(4-8-19)9-11-27/h1-2,5-6,10,12,15-16,19H,3-4,7-9,13-14H2,(H,28,30)(H,29,33)/t16-,19- | PDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | 0.490 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of JAK1-JH1/JH2 domain (574 to 1154 residues) (unknown origin) pre-incubated before NH2-KGGEEEEYFELVKK-CO2 substrate addition and measured... |
J Med Chem 63: 2915-2929 (2020)
Article DOI: 10.1021/acs.jmedchem.9b01439 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM50527406
(CHEMBL4588333 | US10981911, Example 45)Show SMILES Fc1ccc(CNC(=O)Cc2nc3cnc4[nH]ccc4c3n2[C@H]2CC[C@H](CC#N)CC2)cc1 |r,wU:22.24,wD:25.28,(4.15,-4.61,;4.92,-5.95,;6.47,-5.94,;7.24,-7.28,;6.46,-8.6,;7.24,-9.93,;8.78,-9.93,;9.55,-11.26,;8.78,-12.6,;11.09,-11.26,;11.86,-12.6,;11.24,-14,;12.38,-15.02,;12.38,-16.56,;13.71,-17.33,;15.04,-16.56,;16.52,-17.04,;17.43,-15.79,;16.52,-14.53,;15.04,-15.01,;13.7,-14.25,;13.38,-12.75,;14.41,-11.61,;13.94,-10.15,;14.97,-9,;16.48,-9.33,;17.52,-8.18,;19.02,-8.51,;20.53,-8.84,;16.95,-10.79,;15.93,-11.93,;4.93,-8.62,;4.16,-7.29,)| Show InChI InChI=1S/C25H25FN6O/c26-18-5-1-17(2-6-18)14-29-23(33)13-22-31-21-15-30-25-20(10-12-28-25)24(21)32(22)19-7-3-16(4-8-19)9-11-27/h1-2,5-6,10,12,15-16,19H,3-4,7-9,13-14H2,(H,28,30)(H,29,33)/t16-,19- | PDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | 28 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of JAK2/JAK2 in human PBMC assessed as reduction in GM-CSF-induced STAT5 phosphorylation pre-incubated for 30 mins before GM-CSF stimulati... |
J Med Chem 63: 2915-2929 (2020)
Article DOI: 10.1021/acs.jmedchem.9b01439 |
More data for this
Ligand-Target Pair | |
JAK3/JAK1
(Homo sapiens (Human)) | BDBM50527406
(CHEMBL4588333 | US10981911, Example 45)Show SMILES Fc1ccc(CNC(=O)Cc2nc3cnc4[nH]ccc4c3n2[C@H]2CC[C@H](CC#N)CC2)cc1 |r,wU:22.24,wD:25.28,(4.15,-4.61,;4.92,-5.95,;6.47,-5.94,;7.24,-7.28,;6.46,-8.6,;7.24,-9.93,;8.78,-9.93,;9.55,-11.26,;8.78,-12.6,;11.09,-11.26,;11.86,-12.6,;11.24,-14,;12.38,-15.02,;12.38,-16.56,;13.71,-17.33,;15.04,-16.56,;16.52,-17.04,;17.43,-15.79,;16.52,-14.53,;15.04,-15.01,;13.7,-14.25,;13.38,-12.75,;14.41,-11.61,;13.94,-10.15,;14.97,-9,;16.48,-9.33,;17.52,-8.18,;19.02,-8.51,;20.53,-8.84,;16.95,-10.79,;15.93,-11.93,;4.93,-8.62,;4.16,-7.29,)| Show InChI InChI=1S/C25H25FN6O/c26-18-5-1-17(2-6-18)14-29-23(33)13-22-31-21-15-30-25-20(10-12-28-25)24(21)32(22)19-7-3-16(4-8-19)9-11-27/h1-2,5-6,10,12,15-16,19H,3-4,7-9,13-14H2,(H,28,30)(H,29,33)/t16-,19- | PDB
UniProtKB/SwissProt
UniProtKB/TrEMBL
antibodypedia
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | 2.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of JAK1/JAK3 in human PBMC assessed as reduction in IL2-induced STAT5 phosphorylation pre-incubated for 30 mins before IL2 stimulation for... |
J Med Chem 63: 2915-2929 (2020)
Article DOI: 10.1021/acs.jmedchem.9b01439 |
More data for this
Ligand-Target Pair | |
TYK2 [aa 580-1182,C936A,C1142A]
(Homo sapiens (Human)) | BDBM50527406
(CHEMBL4588333 | US10981911, Example 45)Show SMILES Fc1ccc(CNC(=O)Cc2nc3cnc4[nH]ccc4c3n2[C@H]2CC[C@H](CC#N)CC2)cc1 |r,wU:22.24,wD:25.28,(4.15,-4.61,;4.92,-5.95,;6.47,-5.94,;7.24,-7.28,;6.46,-8.6,;7.24,-9.93,;8.78,-9.93,;9.55,-11.26,;8.78,-12.6,;11.09,-11.26,;11.86,-12.6,;11.24,-14,;12.38,-15.02,;12.38,-16.56,;13.71,-17.33,;15.04,-16.56,;16.52,-17.04,;17.43,-15.79,;16.52,-14.53,;15.04,-15.01,;13.7,-14.25,;13.38,-12.75,;14.41,-11.61,;13.94,-10.15,;14.97,-9,;16.48,-9.33,;17.52,-8.18,;19.02,-8.51,;20.53,-8.84,;16.95,-10.79,;15.93,-11.93,;4.93,-8.62,;4.16,-7.29,)| Show InChI InChI=1S/C25H25FN6O/c26-18-5-1-17(2-6-18)14-29-23(33)13-22-31-21-15-30-25-20(10-12-28-25)24(21)32(22)19-7-3-16(4-8-19)9-11-27/h1-2,5-6,10,12,15-16,19H,3-4,7-9,13-14H2,(H,28,30)(H,29,33)/t16-,19- | PDB
MMDB
KEGG
B.MOAD
DrugBank
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 12.2 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV
US Patent
| Assay Description
11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... |
US Patent US10981911 (2021)
|
More data for this
Ligand-Target Pair | |
JAK1 (aa 574-1154)
(Homo sapiens (Human)) | BDBM50527406
(CHEMBL4588333 | US10981911, Example 45)Show SMILES Fc1ccc(CNC(=O)Cc2nc3cnc4[nH]ccc4c3n2[C@H]2CC[C@H](CC#N)CC2)cc1 |r,wU:22.24,wD:25.28,(4.15,-4.61,;4.92,-5.95,;6.47,-5.94,;7.24,-7.28,;6.46,-8.6,;7.24,-9.93,;8.78,-9.93,;9.55,-11.26,;8.78,-12.6,;11.09,-11.26,;11.86,-12.6,;11.24,-14,;12.38,-15.02,;12.38,-16.56,;13.71,-17.33,;15.04,-16.56,;16.52,-17.04,;17.43,-15.79,;16.52,-14.53,;15.04,-15.01,;13.7,-14.25,;13.38,-12.75,;14.41,-11.61,;13.94,-10.15,;14.97,-9,;16.48,-9.33,;17.52,-8.18,;19.02,-8.51,;20.53,-8.84,;16.95,-10.79,;15.93,-11.93,;4.93,-8.62,;4.16,-7.29,)| Show InChI InChI=1S/C25H25FN6O/c26-18-5-1-17(2-6-18)14-29-23(33)13-22-31-21-15-30-25-20(10-12-28-25)24(21)32(22)19-7-3-16(4-8-19)9-11-27/h1-2,5-6,10,12,15-16,19H,3-4,7-9,13-14H2,(H,28,30)(H,29,33)/t16-,19- | PDB
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV
US Patent
| Assay Description
11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... |
US Patent US10981911 (2021)
|
More data for this
Ligand-Target Pair | |
JAK2 (aa 532-1132)
(Homo sapiens (Human)) | BDBM50527406
(CHEMBL4588333 | US10981911, Example 45)Show SMILES Fc1ccc(CNC(=O)Cc2nc3cnc4[nH]ccc4c3n2[C@H]2CC[C@H](CC#N)CC2)cc1 |r,wU:22.24,wD:25.28,(4.15,-4.61,;4.92,-5.95,;6.47,-5.94,;7.24,-7.28,;6.46,-8.6,;7.24,-9.93,;8.78,-9.93,;9.55,-11.26,;8.78,-12.6,;11.09,-11.26,;11.86,-12.6,;11.24,-14,;12.38,-15.02,;12.38,-16.56,;13.71,-17.33,;15.04,-16.56,;16.52,-17.04,;17.43,-15.79,;16.52,-14.53,;15.04,-15.01,;13.7,-14.25,;13.38,-12.75,;14.41,-11.61,;13.94,-10.15,;14.97,-9,;16.48,-9.33,;17.52,-8.18,;19.02,-8.51,;20.53,-8.84,;16.95,-10.79,;15.93,-11.93,;4.93,-8.62,;4.16,-7.29,)| Show InChI InChI=1S/C25H25FN6O/c26-18-5-1-17(2-6-18)14-29-23(33)13-22-31-21-15-30-25-20(10-12-28-25)24(21)32(22)19-7-3-16(4-8-19)9-11-27/h1-2,5-6,10,12,15-16,19H,3-4,7-9,13-14H2,(H,28,30)(H,29,33)/t16-,19- | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
B.MOAD
DrugBank
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 6.10 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV
US Patent
| Assay Description
11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... |
US Patent US10981911 (2021)
|
More data for this
Ligand-Target Pair | |
JAK3 (aa 512-1124)
(Homo sapiens (Human)) | BDBM50527406
(CHEMBL4588333 | US10981911, Example 45)Show SMILES Fc1ccc(CNC(=O)Cc2nc3cnc4[nH]ccc4c3n2[C@H]2CC[C@H](CC#N)CC2)cc1 |r,wU:22.24,wD:25.28,(4.15,-4.61,;4.92,-5.95,;6.47,-5.94,;7.24,-7.28,;6.46,-8.6,;7.24,-9.93,;8.78,-9.93,;9.55,-11.26,;8.78,-12.6,;11.09,-11.26,;11.86,-12.6,;11.24,-14,;12.38,-15.02,;12.38,-16.56,;13.71,-17.33,;15.04,-16.56,;16.52,-17.04,;17.43,-15.79,;16.52,-14.53,;15.04,-15.01,;13.7,-14.25,;13.38,-12.75,;14.41,-11.61,;13.94,-10.15,;14.97,-9,;16.48,-9.33,;17.52,-8.18,;19.02,-8.51,;20.53,-8.84,;16.95,-10.79,;15.93,-11.93,;4.93,-8.62,;4.16,-7.29,)| Show InChI InChI=1S/C25H25FN6O/c26-18-5-1-17(2-6-18)14-29-23(33)13-22-31-21-15-30-25-20(10-12-28-25)24(21)32(22)19-7-3-16(4-8-19)9-11-27/h1-2,5-6,10,12,15-16,19H,3-4,7-9,13-14H2,(H,28,30)(H,29,33)/t16-,19- | PDB
MMDB
KEGG
B.MOAD
DrugBank
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 183 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV
US Patent
| Assay Description
11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... |
US Patent US10981911 (2021)
|
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM50527406
(CHEMBL4588333 | US10981911, Example 45)Show SMILES Fc1ccc(CNC(=O)Cc2nc3cnc4[nH]ccc4c3n2[C@H]2CC[C@H](CC#N)CC2)cc1 |r,wU:22.24,wD:25.28,(4.15,-4.61,;4.92,-5.95,;6.47,-5.94,;7.24,-7.28,;6.46,-8.6,;7.24,-9.93,;8.78,-9.93,;9.55,-11.26,;8.78,-12.6,;11.09,-11.26,;11.86,-12.6,;11.24,-14,;12.38,-15.02,;12.38,-16.56,;13.71,-17.33,;15.04,-16.56,;16.52,-17.04,;17.43,-15.79,;16.52,-14.53,;15.04,-15.01,;13.7,-14.25,;13.38,-12.75,;14.41,-11.61,;13.94,-10.15,;14.97,-9,;16.48,-9.33,;17.52,-8.18,;19.02,-8.51,;20.53,-8.84,;16.95,-10.79,;15.93,-11.93,;4.93,-8.62,;4.16,-7.29,)| Show InChI InChI=1S/C25H25FN6O/c26-18-5-1-17(2-6-18)14-29-23(33)13-22-31-21-15-30-25-20(10-12-28-25)24(21)32(22)19-7-3-16(4-8-19)9-11-27/h1-2,5-6,10,12,15-16,19H,3-4,7-9,13-14H2,(H,28,30)(H,29,33)/t16-,19- | PDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | 9.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of JAK2-JH1/JH2 domain (532 to 1132 residues) (unknown origin) pre-incubated before NH2-KGGEEEEYFELVKK-CO2 substrate addition and measured... |
J Med Chem 63: 2915-2929 (2020)
Article DOI: 10.1021/acs.jmedchem.9b01439 |
More data for this
Ligand-Target Pair | |
Search and Browse
